AngioDynamics (ANGO) Q2 2026 earnings review
Profitability Inflection Overshadows Tech Deceleration
AngioDynamics delivered a 'clean' beat-and-raise quarter, driven by strict cost discipline and unexpected strength in its legacy Medical Device segment. Adjusted EBITDA nearly doubled YoY to $5.9M, and the company generated positive cash flow earlier than expected. However, the growth narrative has a crack in the armor: the high-flying Mechanical Thrombectomy segment decelerated sharply from >40% growth in Q1 to just 3.9% in Q2. CEO Jim Clemmer announced his retirement, adding leadership uncertainty to a company midway through a strategic transformation.
🐂 Bull Case
The company generated $4.7M in cash during Q2 and raised FY26 Adjusted EBITDA guidance to $8.0-$10.0M. Gross margins expanded 170bps YoY to 56.4%, proving the shift to higher-margin Med Tech products is lifting the bottom line despite tariff headwinds.
The Medical Device segment, previously guided to be flat, grew 5.6% YoY. This stability provides crucial cash flow to fund the growth portfolio.
🐻 Bear Case
After multiple quarters of ~40% growth, the Mechanical Thrombectomy business (AngioVac/AlphaVac) slammed the brakes, growing only 3.9% YoY and declining sequentially ($11.3M in Q1 to $11.0M in Q2). This raises concerns about competition or saturation.
CEO Jim Clemmer's retirement announcement creates uncertainty. While he will stay until a successor is found, executive transitions often lead to strategic pauses or execution variability.
⚖️ Verdict: ⚪
Neutral. The profitability improvements are excellent, but the sudden stalling of the Mechanical Thrombectomy growth engine—previously the star performer—is a significant concern that dampens the enthusiasm for the guidance raise.
Key Themes
Mechanical Thrombectomy Growth Shock
Decelerating. The Mechanical Thrombectomy (MT) portfolio has been the company's primary growth story. In Q1, it grew 41% YoY. In Q2, growth evaporated to just 3.9% ($11.0M). This sudden deceleration suggests either tough competitive dynamics or integration issues with the new sales force structure. While management cited 'solid performance,' the data indicates a break in trend.
Auryon & NanoKnife Resilience
Stable. While Thrombectomy slowed, the other two legs of the Med Tech stool held up. Auryon (Atherectomy) grew 18.6% YoY to $16.3M. NanoKnife surged 22.2% YoY to $7.3M. The NanoKnife performance is particularly notable ahead of the Jan 1, 2026 effective date for new CPT codes, suggesting early organic adoption is building momentum.
Operational Efficiency & Cash Flow
Accelerating. The company ended Q2 with $41.6M in cash, up from $38.8M in Q1, defying expectations of cash burn in the first half. Gross margins improved 170 basis points YoY to 56.4%. This efficiency is driven by the mix shift to Med Tech and manufacturing transfer initiatives, allowing them to raise EBITDA guidance.
Tariff Exposure
Stable. The company reiterated its expectation of a $4.0 - $6.0 million impact from tariffs for FY26. While margins improved in Q2, this remains a headwind to further expansion. Management noted assumptions are based on the 'current tariff situation' as of Jan 6, 2026, leaving exposure to future policy shifts.
Leadership Transition
CEO Jim Clemmer is retiring after a decade. While the search is ongoing and he will remain in place, this signals the end of the initial 'transformation' phase. The incoming CEO will face the task of scaling the Med Tech business—specifically fixing the Thrombectomy growth trajectory.
Other KPIs
Accelerating. Surprisingly strong growth of 5.6% YoY (vs flat guidance). This segment was expected to be a managed decline or flat cash cow, but it is currently contributing to the top-line beat.
Stable. Continued strength here (up from 63.7% last year) confirms the thesis that as Med Tech grows as a % of total revenue, the overall corporate margin profile structurally improves.
Stable/Improving. Cash balance increased sequentially from $38.8M in Q1. Zero debt. The company is successfully self-funding its growth initiatives.
Guidance
Accelerating. Raised from $308-$313M. The increase is driven primarily by the Medical Device segment outperformance, as Med Tech growth guidance percentage was left unchanged.
Accelerating. Midpoint raised from $8.0M to $9.0M. Implies continued margin discipline in H2.
Stable. Despite the weak Q2 for Thrombectomy, management held the full-year growth target. Given Q1 grew 26% and Q2 grew 13%, H2 needs to average ~10-12% to hit the midpoint, suggesting management expects the deceleration to stabilize.
Accelerating. Up from 'Flat'. Q2 actual was +5.6%, so the full-year guide of 0-1% implies a significant deceleration (or conservatism) for H2.
Key Questions
Mechanical Thrombectomy Crash
Revenue growth for MT dropped from 41% in Q1 to 3.9% in Q2. What specifically caused this rapid deceleration? Was it lost accounts, utilization drops, or a one-time order timing issue?
Implied H2 Deceleration
Guidance implies Med Device growth will slow significantly in H2 (from +5.6% in Q2 to ~0% for the year). Is Q2's strength sustainable, or was there pull-forward demand?
AlphaVac Blood Return
Can you provide an update on the FDA status of the AlphaVac blood return system? Is the lack of this feature hindering growth against competitors like Inari?
CEO Transition Timeline
With the CEO search underway, are there any strategic initiatives that will be paused until a successor is seated?